Developing and Evaluating ASTHMAXcel Adventures: A Novel Gamified Mobile Application for Pediatric Patients with Asthma
Overview
Pulmonary Medicine
Authors
Affiliations
Background: The ASTHMAXcel mobile application has been linked to favorable outcomes among adult patients with asthma.
Objective: To assess the impact of ASTHMAXcel Adventures, a gamified, guideline-based, pediatric version on asthma control, knowledge, health care utilization, and patient satisfaction.
Methods: Pediatric patients with asthma received the ASTHMAXcel Adventures mobile intervention on-site only at baseline (visit 1), 4 months (visit 2), and 6 months (visit 3). The asthma control test, asthma illness representation scale-self-administered, pediatric asthma impact survey, and Client Satisfaction Questionnaire-8 were used to assess asthma control, knowledge, and patient satisfaction. Patients reported the number of asthma-related emergency department (ED) visits, hospitalizations, and oral prednisone use.
Results: A total of 39 patients completed the study. The proportion of controlled asthma increased from visit 1 to visits 2 and 3 (30.8% vs 53.9%, P = .04; 30.8% vs 59.0%, P = .02), and largely seen in boys. The mean asthma illness representation scale-self-administered scores increased from baseline pre- to postintervention, with sustained improvements at visits 2 and 3 (3.55 vs 3.76, P < .001; 3.55 vs 3.80, P = .001; 3.55 vs 3.99, P < .001). The pediatric asthma impact survey scores improved from baseline to visits 2 and 3 (43.33 vs 34.08, P < .001; 43.33 vs 31.74, P < .001). ED visits and prednisone use significantly decreased from baseline to visits 2 and 3 (ED: 0.46 vs 0.13, P = .03; 0.46 vs 0.02, P = .02; prednisone use, 0.49 vs 0.13, P = .02; 0.49 vs 0.03, P = .003. Satisfaction was high with mean client satisfaction questionnaire score of approximately 30 (out of 32) at all visits.
Conclusion: ASTHMAXcel Adventures improved asthma control, knowledge, and quality of life, and reduced ED visits and prednisone use with high satisfaction scores.
Feldman J, Rastogi D, Warman K, Serebrisky D, Arcoleo K Ann Am Thorac Soc. 2024; 22(3):403-415.
PMID: 39454196 PMC: 11892664. DOI: 10.1513/AnnalsATS.202406-637OC.
Berlot A, Chen P, Kaur S, Mowrey W, Mahali L, Gonzalez J Clin Diabetes. 2024; 42(2):232-242.
PMID: 38694246 PMC: 11060611. DOI: 10.2337/cd23-0034.
Sapouna V, Kitixis P, Petrou E, Michailidou T, Dalamarinis P, Kortianou E J Bras Pneumol. 2023; 49(5):e20230201.
PMID: 37909552 PMC: 10759968. DOI: 10.36416/1806-3756/e20230201.
Why the role of mHealth in allergy diagnosis and treatment adherence cannot be overlooked.
Szylling A, Raciborski F, Wojas O, Furmanczyk K, Krzych-Falta E, Bousquet J Clin Transl Allergy. 2023; 13(10):e12298.
PMID: 37876036 PMC: 10580813. DOI: 10.1002/clt2.12298.
Silverstein G, Styke S, Kaur S, Singh A, Green S, Jariwala S Psychosom Med. 2023; 85(7):605-611.
PMID: 36799736 PMC: 10372190. DOI: 10.1097/PSY.0000000000001170.